ALOPRIM Drug Patent Profile
✉ Email this page to a colleague
When do Aloprim patents expire, and when can generic versions of Aloprim launch?
Aloprim is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in ALOPRIM is allopurinol sodium. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aloprim
A generic version of ALOPRIM was approved as allopurinol sodium by HIKMA on August 26th, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ALOPRIM?
- What are the global sales for ALOPRIM?
- What is Average Wholesale Price for ALOPRIM?
Summary for ALOPRIM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Clinical Trials: | 3 |
| Patent Applications: | 328 |
| Drug Prices: | Drug price information for ALOPRIM |
| What excipients (inactive ingredients) are in ALOPRIM? | ALOPRIM excipients list |
| DailyMed Link: | ALOPRIM at DailyMed |
Recent Clinical Trials for ALOPRIM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Washington University School of Medicine | Phase 1/Phase 2 |
| University of California, San Francisco | Phase 4 |
| Open Medicine Institute | Phase 4 |
Pharmacology for ALOPRIM
| Drug Class | Xanthine Oxidase Inhibitor |
| Mechanism of Action | Xanthine Oxidase Inhibitors |
US Patents and Regulatory Information for ALOPRIM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | ALOPRIM | allopurinol sodium | INJECTABLE;INJECTION | 020298-001 | May 17, 1996 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
